Samsung Biologics Financials
| 207940 Stock | 803,000 7,000 0.86% |
Samsung |
Understanding current and past Samsung Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Samsung Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in Samsung Biologics' assets may result in an increase in income on the income statement.
The data published in Samsung Biologics' official financial statements typically reflect Samsung Biologics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Samsung Biologics' quantitative information. For example, before you start analyzing numbers published by Samsung accountants, it's essential to understand Samsung Biologics' liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the presentation of Samsung Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Samsung Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Samsung Biologics' management manipulating its earnings.
| Foreign Associate | Korea |
| Instrument | Korea Stock View All |
| Exchange | Korea Stock Exchange |
| ISIN | KR7207940008 |
| Business Address | 300 Songdo bio |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.samsungbiologics.com |
| Phone | (82) 33 455 3825 |
You should never invest in Samsung Biologics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Samsung Stock, because this is throwing your money away. Analyzing the key information contained in Samsung Biologics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Samsung Biologics Key Financial Ratios
Samsung Biologics' financial ratios allow both analysts and investors to convert raw data from Samsung Biologics' financial statements into concise, actionable information that can be used to evaluate the performance of Samsung Biologics over time and compare it to other companies across industries.| Return On Equity | 0.0751 | |||
| Return On Asset | 0.0422 | |||
| Target Price | 1000000.0 | |||
| Number Of Employees | 10 | |||
| Beta | 0.58 |
Samsung Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Samsung Biologics's current stock value. Our valuation model uses many indicators to compare Samsung Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Samsung Biologics competition to find correlations between indicators driving Samsung Biologics's intrinsic value. More Info.Samsung Biologics Co is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers reporting about 0.56 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Samsung Biologics Co is roughly 1.78 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Samsung Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Samsung Biologics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Samsung Biologics Systematic Risk
Samsung Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Samsung Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Samsung Biologics correlated with the market. If Beta is less than 0 Samsung Biologics generally moves in the opposite direction as compared to the market. If Samsung Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Samsung Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Samsung Biologics is generally in the same direction as the market. If Beta > 1 Samsung Biologics moves generally in the same direction as, but more than the movement of the benchmark.
Samsung Biologics July 6, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Samsung Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Samsung Biologics Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Samsung Biologics Co based on widely used predictive technical indicators. In general, we focus on analyzing Samsung Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Samsung Biologics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 6.72 | |||
| Value At Risk | (1.87) | |||
| Potential Upside | 2.69 |
Complementary Tools for Samsung Stock analysis
When running Samsung Biologics' price analysis, check to measure Samsung Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Samsung Biologics is operating at the current time. Most of Samsung Biologics' value examination focuses on studying past and present price action to predict the probability of Samsung Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Samsung Biologics' price. Additionally, you may evaluate how the addition of Samsung Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |